Neometic is a specialized company that develops and manufactures hospital-grade cosmetics and skin boosters based on proprietary anti-aging technologies. Led directly by its CEO, who holds a background in materials science from POSTECH (Pohang University of Science and Technology), the company focuses on developing high-performance products that can be immediately utilized in clinical environments. Rather than positioning its products as simple cosmetics, Neometic’s core strategy centers on designing solutions capable of generating measurable revenue structures within dermatology clinics and hospitals, enabling rapid expansion in both domestic and global medical aesthetic markets.
Its flagship skin booster, Collaster, has established stable references by being adopted by more than 70 dermatology clinics and hospitals in Korea within one year of launch. With differentiated strengths—including a structure that contributes to hospital revenue growth, repeat-purchase–based usage, and six customized formulations—Collaster has positioned itself not merely as a consumable product but as a key solution capable of driving clinic profitability.
Collaster is available in six variants: Original, PDRN, AC Solution, Brightening, Pore Tightening, and Nexosome, allowing flexible protocol design according to skin type and treatment objectives. In particular, when used in combination with energy-based devices such as Potenza and MTS, it demonstrates strong synergistic effects, forming a structure that enhances patient satisfaction and encourages repeat visits. Some clinics have reported meaningful monthly revenue performance, validating the product’s competitiveness.
Neometic’s technological capabilities are also being recognized in the B2C market. Its EGF-based anti-aging regenerative cream, EGF Regencell Cream, achieved seven consecutive sell-outs within less than a year of launch, demonstrating that hospital-grade, technology-based products can also secure strong demand in the consumer market. This case highlights the scalability of Neometic’s proprietary material technologies.
From a technological standpoint, Neometic has secured research results based on HA-EGF conjugation technology, improving EGF skin delivery efficiency and anti-aging effects by approximately three times compared to conventional methods. A next-generation skin booster incorporating this technology is currently under development, with global market launch targeted for 2026. Beyond product distribution, Neometic is simultaneously conducting research on proprietary materials that can potentially expand into medical device applications, pursuing long-term growth as a technology-driven company.
The company is also achieving progress in overseas markets. After completing cosmetic manufacturing and sales registration with Japan’s Ministry of Health, exports through hospital channels began in 2025. With Malaysia’s NPRA registration secured, supply has expanded across Southeast Asia. Regulatory compliance in major markets—including European CPNP registration and U.S. MoCRA registration—has been proactively completed, establishing a foundation for global distribution. Exports are currently active in Japan, Malaysia, and Thailand, with partnership discussions underway in European markets such as France.
Through this exhibition, Neometic aims to expand partnerships in countries where regulatory approvals have already been completed while identifying strategic collaborators for entry into new overseas markets. Rather than focusing solely on short-term export performance, the company seeks to establish sustainable global networks by securing long-term partners suited to each country’s distribution structure and medical aesthetic environment.
Going forward, Neometic plans to continue participating in major international medical and aesthetic exhibitions to expand engagement with global buyers, strengthening its brand presence through skin booster solutions that demonstrably contribute to hospital revenue. Through this strategy, Neometic aims to achieve stable growth not only in Korea but also across global markets as a technology-based medical aesthetic company.